Tag Archives: Eli Lilly
Pharma's Influence on the Super Committee: Is Cash Really King?
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
Posted in Strategy, healthcare, leadership Also tagged Congress, deficit, Pfizer, PhRMA, Politics, Super Committee 1 Comment
DIA: Does Six Sigma Stifle R&D Innovation?
Can the management style known as Six Sigma help improve the probability of a drug’s commercial success, or do its black-belted acolytes punch holes in the creative process needed for innovative R&D discovery?
Abbott Shells Out $3.7 Billion for Piramal
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy Also tagged Abbott, branded generics, Diabetes, Emerging Markets, generics, india, Merck, Oncology, Piramal Leave a comment
Lower Lilly Earnings the Shape of Things to Come
Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05 billion—net income fell 5 percent to $1.25 billion.
Part of the blame for that 4 percent difference, the company said, lies with the passage of [...]
Posted in Strategy Also tagged Earnings, Effexor, John Lechleiter, Lipitor, pricing, Seroquel Leave a comment

Lilly's Decentralized Global Launch Strategy